Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells

J. Lawrence; C. Saba; R. Gogal; O. Lamberth; M. L. Vandenplas; D. J. Hurley; P. Dubreuil; O. Hermine; K. Dobbin; M. Turek

doi:10.1111/j.1476-5829.2011.00291.x

Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells

J. Lawrence, C. Saba, R. Gogal, O. Lamberth, M. L. Vandenplas, D. J. Hurley, P. Dubreuil, O. Hermine, K. Dobbin, M. Turek

Veterinary Clinical Sciences

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.

Original language	English (US)
Pages (from-to)	143-154
Number of pages	12
Journal	Veterinary and Comparative Oncology
Volume	10
Issue number	2
DOIs	https://doi.org/10.1111/j.1476-5829.2011.00291.x
State	Published - Jun 2012

Keywords

Cat
Injection-site sarcoma
Masitinib
Platelet-derived growth factor receptor
Tyrosine kinase inhibitor
Vaccine-associated sarcoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/j.1476-5829.2011.00291.x

OpenUrl availability

Full text

Cite this

Lawrence, J., Saba, C., Gogal, R., Lamberth, O., Vandenplas, M. L., Hurley, D. J., Dubreuil, P., Hermine, O., Dobbin, K., & Turek, M. (2012). Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Veterinary and Comparative Oncology, 10(2), 143-154. https://doi.org/10.1111/j.1476-5829.2011.00291.x

Lawrence, J, Saba, C, Gogal, R, Lamberth, O, Vandenplas, ML, Hurley, DJ, Dubreuil, P, Hermine, O, Dobbin, K & Turek, M 2012, 'Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells', Veterinary and Comparative Oncology, vol. 10, no. 2, pp. 143-154. https://doi.org/10.1111/j.1476-5829.2011.00291.x

@article{d3b97380805441dab86c4bd0c02c2f99,

title = "Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells",

abstract = "Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.",

keywords = "Cat, Injection-site sarcoma, Masitinib, Platelet-derived growth factor receptor, Tyrosine kinase inhibitor, Vaccine-associated sarcoma",

author = "J. Lawrence and C. Saba and R. Gogal and O. Lamberth and Vandenplas, {M. L.} and Hurley, {D. J.} and P. Dubreuil and O. Hermine and K. Dobbin and M. Turek",

year = "2012",

month = jun,

doi = "10.1111/j.1476-5829.2011.00291.x",

language = "English (US)",

volume = "10",

pages = "143--154",

journal = "Veterinary and Comparative Oncology",

issn = "1476-5810",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells

AU - Lawrence, J.

AU - Saba, C.

AU - Gogal, R.

AU - Lamberth, O.

AU - Vandenplas, M. L.

AU - Hurley, D. J.

AU - Dubreuil, P.

AU - Hermine, O.

AU - Dobbin, K.

AU - Turek, M.

PY - 2012/6

Y1 - 2012/6

N2 - Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.

AB - Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.

KW - Cat

KW - Injection-site sarcoma

KW - Masitinib

KW - Platelet-derived growth factor receptor

KW - Tyrosine kinase inhibitor

KW - Vaccine-associated sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84860343001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860343001&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5829.2011.00291.x

DO - 10.1111/j.1476-5829.2011.00291.x

M3 - Article

C2 - 22236016

AN - SCOPUS:84860343001

SN - 1476-5810

VL - 10

SP - 143

EP - 154

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

IS - 2

ER -

Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this